We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
-5.38%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$530M
AUM Growth
+$88.9M
Cap. Flow
+$121M
Cap. Flow %
22.77%
Top 10 Hldgs %
58.16%
Holding
331
New
70
Increased
91
Reduced
51
Closed
65

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$32.3M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$24M
3
BBIO icon
BridgeBio Pharma
BBIO
+$19.5M
4
ROIV icon
Roivant Sciences
ROIV
+$14.9M
5
RPRX icon
Royalty Pharma
RPRX
+$12.8M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.1M
2
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.3M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$3.85M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$3.78M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 80.42%
2 Financials 1.75%
3 Industrials 0.22%
4 Utilities 0.17%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLSTW
251
DELISTED
Global Star Acquisition, Inc. Warrants
GLSTW
$2.98K ﹤0.01%
120,000
– –
LEXX icon
252
Lexaria Bioscience
LEXX
$8.82M
$2.63K ﹤0.01%
63
-1,712
-96% -$77K
EMCGR
253
DELISTED
Embrace Change Acquisition Corp Rights
EMCGR
$2.48K ﹤0.01%
18,000
– –
AIEV
254
DELISTED
Thunder Power Holdings, Inc. Common Stock
AIEV
$2.48K ﹤0.01%
1,500
-13,500
-90% -$125K
XERS icon
255
Xeris Biopharma Holdings
XERS
$1.27B
$2.25K ﹤0.01%
1,000
-4,149
-81% -$8.36K
RCKT icon
256
Rocket Pharmaceuticals
RCKT
$387M
$2.15K ﹤0.01%
+100
New +$2.3K
CETUR
257
DELISTED
Cetus Capital Acquisition Corp. Right
CETUR
$1.42K ﹤0.01%
4,999
– –
XLO icon
258
Xilio Therapeutics
XLO
$61M
$1.42K ﹤0.01%
+107
New +$1.68K
SBCWW
259
SBC Medical Group Warrants
SBCWW
$2.88M
$1.41K ﹤0.01%
19,800
– –
OAKUW
260
DELISTED
Oak Woods Acquisition Corp Warrant
OAKUW
$750 ﹤0.01%
30,000
– –
ECDAW
261
DELISTED
ECD Automotive Design Warrant
ECDAW
$652 ﹤0.01%
32,596
– –
FTIIW
262
DELISTED
FutureTech II Acquisition Corp. Warrant
FTIIW
$483 ﹤0.01%
30,000
– –
EMCGW
263
DELISTED
Embrace Change Acquisition Corp Warrants
EMCGW
$378 ﹤0.01%
18,000
– –
AIMAW
264
DELISTED
Aimfinity Investment Corp I Warrant
AIMAW
$362 ﹤0.01%
18,000
– –
FORLW
265
DELISTED
Four Leaf Acquisition Corp Warrants
FORLW
$360 ﹤0.01%
7,987
-1,500
-16% -$59
CETUW
266
DELISTED
Cetus Capital Acquisition Corp. Warrant
CETUW
$130 ﹤0.01%
5,000
– –
ACET icon
267
Adicet Bio
ACET
$74.1M
– –
-1,952
Closed -$73.4K
AKBA icon
268
PUT
Akebia Therapeutics
AKBA
$256M
– –
-9,700
Closed -$17.8K
ALNY icon
269
CALL
Alnylam Pharmaceuticals
ALNY
$28.9B
– –
-11,200
Closed -$1.67M
ALNY icon
270
PUT
Alnylam Pharmaceuticals
ALNY
$28.9B
– –
-234,400
Closed -$35M
AMLX icon
271
PUT
Amylyx Pharmaceuticals
AMLX
$2.69B
– –
-31,800
Closed -$90.3K
APLT
272
PUT
DELISTED
Applied Therapeutics
APLT
– –
-30,100
Closed -$205K
AUPH icon
273
Aurinia Pharmaceuticals
AUPH
$2.07B
– –
-2,000
Closed -$10K
AVTX icon
274
Avalo Therapeutics
AVTX
$989M
– –
-6,000
Closed -$131K
BCYC
275
Bicycle Therapeutics
BCYC
$278M
– –
-14,430
Closed -$359K
9 10
11
12 13

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, ADAR1 Capital Management held 331 positions worth $530M, up 20% from $441M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

ADAR1 Capital Management deployed $121M of net new capital in Q2 2024, opening 70 new positions and adding to 91 existing holdings. Its largest new stake was Perceptive Capital Solutions: 750,000 shares worth $7.54M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $28.1M trimmed.

  • ADAR1 Capital Management's largest Q2 2024 buy was Perceptive Capital Solutions: 750,000 shares worth $7.54M.
  • ADAR1 Capital Management added most to Cytokinetics in Q2 2024, an estimated $32.3M increase.
  • ADAR1 Capital Management's biggest Q2 2024 reduction was Alnylam Pharmaceuticals, cutting an estimated $28.1M.
  • ADAR1 Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2024, selling an estimated $13.3M.
  • ADAR1 Capital Management's ten largest holdings make up 58% of its $530M portfolio in Q2 2024.
  • ADAR1 Capital Management opened 70 new positions and closed 65 in Q2 2024.
  • ADAR1 Capital Management's portfolio value rose 20% quarter-over-quarter to $530M.

Based on ADAR1 Capital Management's 13F filing for Q2 2024, filed 13 Aug 2024.